Table of Contents
A quick guide on Change Authorized Agent India requirements, the role of a CDSCO Authorized Agent, and how foreign manufacturers manage this transition.
Yes, a foreign manufacturer can absolutely change its Authorized Agent India appointment whenever business needs, performance concerns, or compliance requirements make a switch necessary. The process is well defined under CDSCO regulations.
Who Is an Authorized Agent in India? An Authorized Agent India is the local representative through whom a foreign Drug or Device manufacturer interacts with Indian regulators, distributors, and patients.
This role is often called an Indian Authorized Representative or a Foreign Manufacturer Representative India, and both terms describe the same regulatory function. Every foreign entity registering a Drug, Medical Device, or cosmetic in India must appoint such an agent before filing any application with CDSCO.
Understanding the Responsibilities of an Authorized Agent helps explain why choosing, and sometimes changing, the right representative matters so much.
Key duties typically include:
· Filing and maintaining registration or licensing applications on behalf of the foreign manufacturer
· Acting as the point of contact for CDSCO queries, inspections, and compliance notices
· Managing pharmacovigilance reporting, including adverse event and PSUR submissions
· Coordinating product recalls, label updates, or safety communications when required
· Maintaining import documentation and liaising with Port Office authorities for consignment clearance
Because these responsibilities carry legal weight, manufacturers must choose agents carefully and be prepared to replace them if performance falls short.
Indian regulations do not lock a foreign manufacturer into a single agent permanently. A Change Authorized Agent India action is legally permitted and common in practice.
Reasons manufacturers often cite for changing agents include:
· Poor responsiveness or delayed regulatory filings by the existing agent
· Business restructuring, mergers, or change in distribution strategy
· Loss of trust due to compliance lapses or documentation errors
· Better commercial terms or expertise offered by an alternative representative
Whatever the reason, the transition must be formally documented and communicated to CDSCO to avoid regulatory gaps.
The relationship between a foreign manufacturer and its representative rests on a Power of Attorney Authorized Agent India document, executed and often apostilled abroad.
This document legally empowers the agent to act, file, and respond on the manufacturer’s behalf before Indian authorities.
When changing agents, the manufacturer must:
· Need to surrender rc and apply for freshExecute a fresh Power of Attorney in favor of the new authorized agent
· Notarize and apostille the new document as per the CDSCO requirements CDSCO
Notifying the CDSCO Authorized Agent change formally is the final and most critical step, since regulators must always know who is currently accountable. (this process can only be completed by the importer CDSCO does not directly deal with foreign manufacturers)
Step Action Responsible Party
1 Decide to terminate existing agent Foreign manufacturer
2 Execute revocation letter Foreign manufacturer
3 Appointing new agent via fresh Power of Attorney Foreign manufacturer
4 Submit change request with supporting documents New authorized agent
5 Review and update of records CDSCO
6 Continuation of ongoing filings New authorized agent
Practical Considerations During the Transition
Manufacturers should avoid gaps in representation, since an unrepresented product can face compliance risk or delayed regulatory responses during the switch.
It is advisable to overlap the outgoing and incoming agents briefly, allowing document handover and continuity of pharmacovigilance records.
· Yes, a Change Authorized Agent India action is fully permitted under Indian Drug and device regulations, and CliniExperts can guide manufacturers through the entire transition
· A CDSCO Authorized Agent must be formally appointed through a valid, notarized Power of Attorney Authorized Agent India document, which CliniExperts helps draft and execute correctly
· The Responsibilities of an Authorized Agent include filings, Pharmacovigilance, and liaison with regulators, and CliniExperts offers experienced teams to manage these duties reliably
· Both the Indian Authorized Representative and the Foreign Manufacturer Representative India terms refer to the same regulatory role that CliniExperts is equipped to fulfil
· Manufacturers should notify CDSCO promptly and avoid representation gaps whenever they change their authorized agent in India, and partnering with CliniExperts ensures a smooth, compliant handover
What a Revised Schedule M raises GMP standards in India, what has changed for manufacturers, and how large firms and MSMEs can prepare for Compliance and CDSCO inspections. Revised Schedule M is the b..
A practical comparison of CDSCO vs FDA vs EMA, explaining how each regulator’s Drug approval process differs and why one Drug needs separate approvals in India, the US and Europe. A Drug approve..
A quick guide on the Class A & B Medical Device manufacturing license — covering State FDA rules, Form MD-3/MD-5, fees, and timelines for manufacturers. Every manufacturer entering India’s..